Tempest Therapeutics Registers Resale of 2.77M Shares and Warrants from Recent Private Placement

summarizeSummary

Tempest Therapeutics filed an S-3 registration statement for the resale of 2.77 million shares of common stock and shares underlying warrants by selling stockholders, fulfilling registration rights from a recent private placement.

check_boxKey Events

• Resale Registration Filed

  Tempest Therapeutics registered 2,777,781 shares of common stock and shares underlying warrants for resale by selling stockholders.

• Significant Potential Dilution

  The registered shares represent approximately 19.36% of the company's outstanding common stock, creating a substantial potential for dilution.

• Fulfills Private Placement Rights

  This S-3 fulfills registration rights granted in connection with a private placement dated March 20, 2026, which included common stock, pre-funded warrants, and Series A and B warrants.

• Company Will Not Receive Direct Proceeds

  The company will not receive any proceeds from the sale of common stock by the selling stockholders, only from the potential cash exercise of warrants.

auto_awesomeAnalysis

This S-3 filing registers 2.77 million shares of common stock and shares underlying warrants for resale by selling stockholders, representing approximately 19.36% of the company's current outstanding shares. These shares originate from a private placement completed on March 20, 2026, which was previously disclosed. While the underlying private placement was crucial for capital given the company's 'going concern' warning, this registration enables investors to sell their holdings, creating a significant overhang on the stock. The company will not receive proceeds from the resale of these common shares, but may receive proceeds from the cash exercise of warrants, though the common warrants are currently out-of-the-money. This substantial potential dilution is a key factor for investors to monitor.